Therapeutic effects of TACI-Ig on rat with adjuvant arthritis

Clinical and Experimental Immunology

Volumn 163, Issue 2, 2011, Pages 225-234

  Wang, D ^a   Chang, Y ^a   Wu, Y ^a   Zhang, L ^a   Yan, S ^a   Xie, G ^a   Qin, Q ^a   Jin, J ^a   Wang, W ^b   Fang, J ^b   Wei, W ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b RC Biotechnologies Ltd   (China)

Author keywords

Adjuvant arthritis; Immunoglobulin; Pro inflammatory cytokine; Spleen; TACI Ig

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 17; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR IMMUNOGLOBULIN FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANKLE JOINT; ARTHRITIS, EXPERIMENTAL; B-CELL ACTIVATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON-GAMMA; INTERLEUKIN-17; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SPLEEN;

EID: 78650807836     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04293.x     Document Type: Article

References (35)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-61.
2. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-81.
3. Dass S, Vital EM, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Exp Opin Pharmacother 2006; 7:2559-70.
4. Boumans MJ, Tak PP. Rituximab treatment in rheumatoid arthritis: how does it work? Arthritis Res Ther 2009; 11:134.
5. Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. Autoimmun Rev 2007; 7:137-42.
6. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Cheromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-7.
7. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167:4710-18.
8. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172:3422-7.
9. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189:1747-56.
10. Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285:260-3.
11. Hahne M, Kataoka T, Schröter M et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188:1185-90.
12. Roth W, Wagenknecht B, Klumpp A et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 2001; 8:403-10.
13. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995-9.
14. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293:2108-11.
15. von Bülow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278:138-41.
16. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190:1697-710.
17. Stohl W, Xu D, Kim KS et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52:2080-91.
18. Roschke V, Sosnovtseva S, Ward CD et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169:4314-21.
19. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44:1313-19.
20. Tan SM, Xu D, Roschke V et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48:982-92.
21. Assi LK, Wong SH, Ludwig A et al. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum 2007; 56:1776-86.
22. Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15:289-302.
23. Seyler TM, Park YW, Takemura S et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115:3083-92.
24. Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116:724-34.
25. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-7.
26. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337:141-7.
27. Tong T, Zhao W, Wu YQ et al. Chicken type II collagen induced immune balance of main subtype of helper T cells in mesenteric lymph node lymphocytes in rats with collagen-induced arthritis. Inflamm Res 2010; 59:369-77.
28. Bouaziz JD, Yanaba K, Venturi GM et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007; 104:20878-83.
29. Wang H, Marsters SA, Baker T et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2:632-7.
30. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999; 90:65-78.
31. Ohata J, Zvaifler NJ, Nishio M et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174:864-70.
32. Reyes LI, León F, González P et al. Dexamethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine 2008; 42:170-8.
33. Zhang W, Wen L, Huang X et al. hsBAFF enhances activity of NK cells by regulation of CD4(+) T lymphocyte function. Immunol Lett 2008; 120:96-102.
34. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003; 48:594-601.
35. Mariño E, Villanueva J, Walters S, Liuwantara D, Mackay F, Grey ST. CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes 2009; 58:1568-77.